Abstract
The DNA binding protein and chromatin structural regulator DEK regulate many cellular processes. These include proliferation, differentiation, apoptosis, senescence, DNA repairing and the maintenance of stem cell phenotype. DEK is increasingly recognized as a crucial player in many steps of cancer initiation and progression, and is precisely regulated by abundant promoting and inhibiting factors directly or indirectly. DEK may serve as an architectural modulating protein to regulate the expression and function of multiple human genes in cancer cells. In this article we have reviewed the specificities and complexities of DEK in the regulation of transcription factors and global chromatin, including its biologic roles in malignant cells, and summarized the current research. The possible use of DEK as a diagnostic marker and drug target in the prevention or treatment of tumors is also discussed.
Keywords: DEK, cancer, gene regulations, biologic roles, diagnostic marker, drug target.
Graphical Abstract
Current Cancer Drug Targets
Title:The Complexity of DEK Signaling in Cancer Progression
Volume: 18 Issue: 3
Author(s): Yong Teng*, Liwei lang and Catherine E. Jauregui
Affiliation:
- Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, Georgia,United States
Keywords: DEK, cancer, gene regulations, biologic roles, diagnostic marker, drug target.
Abstract: The DNA binding protein and chromatin structural regulator DEK regulate many cellular processes. These include proliferation, differentiation, apoptosis, senescence, DNA repairing and the maintenance of stem cell phenotype. DEK is increasingly recognized as a crucial player in many steps of cancer initiation and progression, and is precisely regulated by abundant promoting and inhibiting factors directly or indirectly. DEK may serve as an architectural modulating protein to regulate the expression and function of multiple human genes in cancer cells. In this article we have reviewed the specificities and complexities of DEK in the regulation of transcription factors and global chromatin, including its biologic roles in malignant cells, and summarized the current research. The possible use of DEK as a diagnostic marker and drug target in the prevention or treatment of tumors is also discussed.
Export Options
About this article
Cite this article as:
Teng Yong*, lang Liwei and Jauregui E. Catherine , The Complexity of DEK Signaling in Cancer Progression, Current Cancer Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1568009617666170522094730
DOI https://dx.doi.org/10.2174/1568009617666170522094730 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Modulation of Doxorubicin Mediated Growth Inhibition of Hepatocellular Carcinoma Cells by Platelet Lysates
Anti-Cancer Agents in Medicinal Chemistry Clinical Applications of Mesenchymal Stem Cells in Laryngotracheal Reconstruction
Current Stem Cell Research & Therapy Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Current Medicinal Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) The Immunohistochemical Expression of the E-Cadherin, Alpha-Catenin,Beta-Catenin and Gamma Catenin Proteins in Epithelial Ovarian Tumours: Relationship with Clinicopathologic Parameters and Patient Survival
Current Women`s Health Reviews The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening Defining Features and Exploring Chemical Modifications to Manipulate RNAa Activity
Current Pharmaceutical Biotechnology Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Metabolic Cooperation in Testis as a Pharmacological Target: From Disease to Contraception
Current Molecular Pharmacology